Background Facial erythema in adult patients with atopic dermatitis (AD) presents a persistent therapeutic challenge, often resistant to conventional treatment. Polynucleotides (PN) have anti‐inflammatory and tissue‐repair properties and are being explored for inflammatory dermatoses. Objectives To evaluate the clinical and biophysical efficacy and safety of intradermal PN injections for facial erythema and barrier dysfunction in adults with AD. Methods This prospective pilot study included 19 adults with mild‐to‐moderate AD and visible facial erythema. Participants received three sessions of intradermal PN injections at 3‐week intervals. Clinical assessments were performed at baseline and weeks 3, 6, and 10. Objective parameters included erythema index (EI), melanin index (MI), transepidermal water loss (TEWL), corneometer‐measured hydration, and skin elasticity (R2, R5, R7). The Investigator Global Assessment (IGA), patient satisfaction, and standardized facial imaging were evaluated. Results Significant improvements were observed in TEWL ( χ 2 = 31.16, p < 0.000001), hydration ( χ 2 = 14.56, p = 0.002), and EI ( χ 2 = 26.05, p < 0.001). Skin elasticity showed favorable trends without statistical significance. IGA scores improved significantly ( χ 2 = 26.02, p < 0.00001), while patient satisfaction increased ( χ 2 = 3.44, p = 0.179). No serious adverse events were reported. Conclusion Intradermal PN injection is a safe and potentially effective option for facial erythema in AD patients, leading to improved clinical and biophysical outcomes. Larger controlled trials are warranted. Trial Registration: Korean Clinical Trial Registry (KCT): KCT0011301
Kui Young Park (Thu,) studied this question.